Immunic, Inc

1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA

Phone: +49 89 2080 477 00

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing, Germany

Phone: +49 89 2080 477 00


April 2, 2019

Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10

Planegg-Martinsried, Germany, April 2, 2019 –Immunic AG, a privately held clinical-stage biotechnology company,...

Read More
February 28, 2019

Immunic Therapeutics to Participate in Investor and Medical Conferences in March

Planegg-Martinsried, Germany, February 28, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology...

Read More
February 26, 2019

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis

Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology...

Read More
February 6, 2019

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11

Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company,...

Read More
January 7, 2019

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling...

Read More
November 5, 2018

Immunic enters into a global option and license agreement with Daiichi Sankyo

Immunic AG gains exclusive, worldwide rights to promising drug development program with...

Read More
April 26, 2018

Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis

First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral...

Read More
January 11, 2018

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active...

Read More
December 12, 2017

Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838

Two phase 1 studies for IMU-838 in healthy volunteers have been completed...

Read More
September 5, 2017

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10...

Read More
February 1, 2017

Immunic Adds EUR 4 Million in Funding to Further Boost Development

Series A financing round extended to EUR 21.7 Million Immunic’s investor base...

Read More
January 9, 2017

Immunic strengthens Management Team and Supervisory Board

Two executives with deep understanding of the immunology field, and with experience...

Read More
September 28, 2016

Immunic acquires 4SC’s immunology portfolio

Immunic acquires two promising drug development programs with validated targets known to...

Read More
September 27, 2016

Immunic successfully closes 17.5 million Euro Series A financing round

One of the largest Series A biotech venture capital financings in Germany...

Read More